NSD2 and hematopoietic and lymphoid cell neoplasm: NSD2 is a bona fide oncogene in hematologic cancers and harbors recurrent activating alterations in over 15–20% of multiple myeloma26–28 and 10% of childhood acute lymphoblastic leukemia29–31.